文献速递脑血管病

血浆CLEC-2对急性缺血性卒中患者的预后意义

Prognostic Significance of Plasma CLEC-2 (C-Type Lectin-Like Receptor 2) in Patients With Acute Ischemic Stroke.
PubMed 文献 · Stroke · 2018-12-07

结果显示AIS患者pCLEC-2显著高于健康对照,且升高的pCLEC-2与卒中进展及90天不良预后显著相关,提示其可能作为AIS预后标志物。

要点

  • AIS患者血浆CLEC-2水平显著高于健康对照(P<0.05)。
  • pCLEC-2升高与卒中进展(OR 1.97,95%CI 1.11-3.50)及90天不良预后(OR 1.70,95%CI 1.17-2.48)相关。
  • 最高四分位pCLEC-2者卒中进展风险约为最低四分位的7-8倍。

核心结论

  • 升高的血浆CLEC-2与卒中进展及90天不良预后显著相关,提示其在AIS中的预后价值,但尚需大规模研究证实。

研究设计与样本

  • 卒中进展定义为发病7天内任何新发神经症状/体征或神经功能恶化;不良预后定义为90天改良Rankin量表评分>2。
  • 采用回归模型评估pCLEC-2与卒中进展/预后的关联。

主要发现

  • AIS患者pCLEC-2水平显著高于健康对照(P<0.05)。
  • 进展性卒中或不良预后患者的pCLEC-2水平显著高于稳定卒中或良好预后者(均P<0.05)。
  • pCLEC-2升高与卒中进展风险增加相关(OR 1.97;95%CI 1.11-3.50;P=0.021)。
  • pCLEC-2升高与不良预后风险增加相关(OR 1.70;95%CI 1.17-2.48;P=0.006)。
  • 最高pCLEC-2水平者卒中进展风险为最低四分位的7-8倍(OR 7.69;95%CI 1.43-41.41),90天不良预后风险亦更高(OR 5.58;95%CI 1.76-17.68)。

关键数值与推荐

  • 预测卒中进展的pCLEC-2最佳截断值为235.48 pg/mL。
  • 预测不良预后的pCLEC-2最佳截断值为207.08 pg/mL。

临床怎么用

  • pCLEC-2或可作为急性缺血性卒中患者卒中进展和90天不良预后的辅助预测指标。
  • 需结合常规风险因素综合评估,不宜单独依据pCLEC-2做出临床决策。

局限性

  • 结论尚需大规模研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- CLEC-2 (C-type lectin-like receptor 2) is a C-type lectin receptor highly expressed on platelets with the prominent involvement in platelet activation, which was increased in coronary heart disease. Given the role of platelet activation in ischemic stroke and the connections between coronary heart disease and ischemic stroke, CLEC-2 might be a candidate marker of ischemic stroke. Here, we aimed to examine the prognostic significance of CLEC-2 in patients with acute ischemic stroke (AIS). Methods- Three hundred fifty-two patients with AIS within 7 days and 112 healthy controls were prospectively studied. Plasma CLEC-2 (pCLEC-2) and some conventional risk factors of stroke were examined. Stroke progression was defined as any new neurological symptoms/signs or any neurological worsening within 7 days after stroke onset, and poor prognosis was defined as modified Rankin Scale scores >2 at 90 days. The association between pCLEC-2 and stroke progression/prognosis was evaluated using regression models. Results- Patients with AIS had a significantly higher level of pCLEC-2 than that of healthy controls (P<0.05). Patients with AIS with progressive stroke or poor prognosis had a much higher level of pCLEC-2 compared with those with stable stroke or good prognosis (all P<0.05). Increasing pCLEC-2 was significantly associated with an increased risk of stroke progression (odds ratio, 1.97; 95% CI, 1.11-3.50; P=0.021) and poor prognosis (odds ratio, 1.70; 95% CI, 1.17-2.48; P=0.006). Patients with the highest pCLEC-2 level were 7- to 8-fold more likely to have stroke progression compared with the lowest quartile (odds ratio, 7.69; 95% CI, 1.43-41.41). Patients with the highest pCLEC-2 level were also more likely to have poor prognosis at 90 days (odds ratio, 5.58; 95% CI, 1.76-17.68). The optimal cutoff points of pCLEC-2 for predicting stroke progression and poor prognosis were 235.48 and 207.08 pg/mL, respectively. Conclusions- Increased pCLEC-2 was associated with stroke progression and poor prognosis at 90 days significantly, which indicates the prognostic role of pCLEC-2 in AIS. However, it needs to be confirmed in large-scale studies.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhang X, Zhang W, Wu X, et al. Prognostic Significance of Plasma CLEC-2 (C-Type Lectin-Like Receptor 2) in Patients With Acute Ischemic Stroke. Stroke. 2018. PMID: 30580704. doi:10.1161/STROKEAHA.118.022563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。